{"title":"元分析:1型糖尿病患者乳糜泻的全球患病率。","authors":"Sahand Karimzadhagh, Elahe Abbaspour, Maryam Shahriarinamin, Pourya Shamsi, Selvana Poursadrolah, Mehrdad Khorasani, Mahzad Daghighi, Arash Malek, Jouan Taheri Talesh, Govind K Makharia, Mohammad Rostami-Nejad","doi":"10.1111/apt.18373","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Coeliac disease (CD) is common in patients with type 1 diabetes (T1D), but prevalence varies globally due to differing screening protocols. There have been substantial changes in screening guidelines over the past two decades.</p><p><strong>Aim: </strong>To evaluate CD prevalence in patients with T1D, focusing on screening studies using antitissue transglutaminase (anti-tTG) antibody.</p><p><strong>Methods: </strong>We searched PubMed, Web of Science, Embase and Scopus for studies published up to 11 December 2023 using keywords related to CD and diabetes. We used random-effects models for overall prevalence and all subgroups, with heterogeneity assessed using Cochran's Q test and the I<sup>2</sup> statistic performed in STATA 18.</p><p><strong>Results: </strong>We included 106 articles involving 65,102 T1D patients across 40 countries. The pooled CD seroprevalence and confirmed CD prevalence were 9% (95% confidence interval, CI, 8%-10%) and 6% (95% CI 5%-7%), respectively. The prevalence was higher in females and children. Denmark, Saudi Arabia and Libya exhibited the highest prevalence (11%), followed by India and Egypt (10%). Belgium, France, Germany, South Africa and the United States had the lowest prevalence (2%). High-income countries showed significantly a lower CD prevalence than middle-income countries (p = 0.03). Meta-regression based on the Human Development Index (HDI) indicated that countries with higher HDI have lower seroprevalence and confirmed CD prevalence.</p><p><strong>Conclusion: </strong>Approximately 1 in 16 patients globally and 1 in 12 patients in Asia and the Middle East with T1D has CD. We suggest that all patients with T1D should be screened for CD.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":" ","pages":"8-31"},"PeriodicalIF":6.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Meta-Analysis: Global Prevalence of Coeliac Disease in Type 1 Diabetes.\",\"authors\":\"Sahand Karimzadhagh, Elahe Abbaspour, Maryam Shahriarinamin, Pourya Shamsi, Selvana Poursadrolah, Mehrdad Khorasani, Mahzad Daghighi, Arash Malek, Jouan Taheri Talesh, Govind K Makharia, Mohammad Rostami-Nejad\",\"doi\":\"10.1111/apt.18373\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Coeliac disease (CD) is common in patients with type 1 diabetes (T1D), but prevalence varies globally due to differing screening protocols. There have been substantial changes in screening guidelines over the past two decades.</p><p><strong>Aim: </strong>To evaluate CD prevalence in patients with T1D, focusing on screening studies using antitissue transglutaminase (anti-tTG) antibody.</p><p><strong>Methods: </strong>We searched PubMed, Web of Science, Embase and Scopus for studies published up to 11 December 2023 using keywords related to CD and diabetes. We used random-effects models for overall prevalence and all subgroups, with heterogeneity assessed using Cochran's Q test and the I<sup>2</sup> statistic performed in STATA 18.</p><p><strong>Results: </strong>We included 106 articles involving 65,102 T1D patients across 40 countries. The pooled CD seroprevalence and confirmed CD prevalence were 9% (95% confidence interval, CI, 8%-10%) and 6% (95% CI 5%-7%), respectively. The prevalence was higher in females and children. Denmark, Saudi Arabia and Libya exhibited the highest prevalence (11%), followed by India and Egypt (10%). Belgium, France, Germany, South Africa and the United States had the lowest prevalence (2%). High-income countries showed significantly a lower CD prevalence than middle-income countries (p = 0.03). Meta-regression based on the Human Development Index (HDI) indicated that countries with higher HDI have lower seroprevalence and confirmed CD prevalence.</p><p><strong>Conclusion: </strong>Approximately 1 in 16 patients globally and 1 in 12 patients in Asia and the Middle East with T1D has CD. We suggest that all patients with T1D should be screened for CD.</p>\",\"PeriodicalId\":121,\"journal\":{\"name\":\"Alimentary Pharmacology & Therapeutics\",\"volume\":\" \",\"pages\":\"8-31\"},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alimentary Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/apt.18373\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.18373","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:乳糜泻(CD)在 1 型糖尿病(T1D)患者中很常见,但由于筛查方案不同,全球的患病率也不尽相同。目的:评估 CD 在 T1D 患者中的患病率,重点关注使用抗组织转谷氨酰胺酶(抗-tTG)抗体进行的筛查研究:我们使用 CD 和糖尿病相关关键词检索了 PubMed、Web of Science、Embase 和 Scopus 上截至 2023 年 12 月 11 日发表的研究。我们使用随机效应模型对总体患病率和所有亚组进行了分析,并使用Cochran's Q检验和STATA 18中的I2统计量对异质性进行了评估:我们共纳入了 106 篇文章,涉及 40 个国家的 65,102 名 T1D 患者。汇总的CD血清流行率和确诊的CD流行率分别为9%(95%置信区间,CI,8%-10%)和6%(95% CI,5%-7%)。女性和儿童的发病率较高。丹麦、沙特阿拉伯和利比亚的患病率最高(11%),其次是印度和埃及(10%)。比利时、法国、德国、南非和美国的患病率最低(2%)。高收入国家的 CD 患病率明显低于中等收入国家(p = 0.03)。基于人类发展指数(HDI)的元回归表明,人类发展指数较高的国家血清阳性反应率和确诊的 CD 感染率较低:全球每 16 名 T1D 患者中约有 1 人患有 CD,亚洲和中东每 12 名患者中约有 1 人患有 CD。我们建议对所有 T1D 患者进行 CD 筛查。
Meta-Analysis: Global Prevalence of Coeliac Disease in Type 1 Diabetes.
Background: Coeliac disease (CD) is common in patients with type 1 diabetes (T1D), but prevalence varies globally due to differing screening protocols. There have been substantial changes in screening guidelines over the past two decades.
Aim: To evaluate CD prevalence in patients with T1D, focusing on screening studies using antitissue transglutaminase (anti-tTG) antibody.
Methods: We searched PubMed, Web of Science, Embase and Scopus for studies published up to 11 December 2023 using keywords related to CD and diabetes. We used random-effects models for overall prevalence and all subgroups, with heterogeneity assessed using Cochran's Q test and the I2 statistic performed in STATA 18.
Results: We included 106 articles involving 65,102 T1D patients across 40 countries. The pooled CD seroprevalence and confirmed CD prevalence were 9% (95% confidence interval, CI, 8%-10%) and 6% (95% CI 5%-7%), respectively. The prevalence was higher in females and children. Denmark, Saudi Arabia and Libya exhibited the highest prevalence (11%), followed by India and Egypt (10%). Belgium, France, Germany, South Africa and the United States had the lowest prevalence (2%). High-income countries showed significantly a lower CD prevalence than middle-income countries (p = 0.03). Meta-regression based on the Human Development Index (HDI) indicated that countries with higher HDI have lower seroprevalence and confirmed CD prevalence.
Conclusion: Approximately 1 in 16 patients globally and 1 in 12 patients in Asia and the Middle East with T1D has CD. We suggest that all patients with T1D should be screened for CD.
期刊介绍:
Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.